Bank of America’s $7 target on LENZ

LENZ Lenz Therapeutics Inc

$4.6 → $7 (+52%) by Aug 2027

Neutral · lowers · said Aug 13, 2026 · 12-month default horizon

Open: judged on the close on Aug 13, 2027

The article this target came from

Lenz stock drops as Bank of America downgrades (LENZ:NASDAQ)

seekingalpha.com · Aug 13, 2026

BofA cut the price target sharply from $31 to $7, citing concerns about the slow commercial uptake of its presbyopia treatment, VIZZ.

Bank of America’s track record → Lenz Therapeutics Inc →

A fact about what Bank of America published, as reported by seekingalpha.com, not a recommendation from Dalsna Finance; Bank of America is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.